PortfoliosLab logoPortfoliosLab logo
ANRO vs. TOI
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

ANRO vs. TOI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Alto Neuroscience, Inc (ANRO) and The Oncology Institute, Inc. (TOI). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

ANRO vs. TOI - Yearly Performance Comparison


2026 (YTD)20252024
ANRO
Alto Neuroscience, Inc
26.29%320.80%-79.57%
TOI
The Oncology Institute, Inc.
-13.76%1,052.10%-85.56%

Fundamentals

Market Cap

ANRO:

$717.64M

TOI:

$3.11B

EPS

ANRO:

-$2.20

TOI:

-$0.06

Total Revenue (TTM)

ANRO:

$0.00

TOI:

$502.73M

Gross Profit (TTM)

ANRO:

-$421.00K

TOI:

$53.67M

EBITDA (TTM)

ANRO:

-$61.63M

TOI:

-$39.77M

Returns By Period

In the year-to-date period, ANRO achieves a 26.29% return, which is significantly higher than TOI's -13.76% return.


ANRO

1D
12.51%
1M
14.17%
YTD
26.29%
6M
459.20%
1Y
940.74%
3Y*
5Y*
10Y*

TOI

1D
8.48%
1M
6.23%
YTD
-13.76%
6M
-12.03%
1Y
169.30%
3Y*
65.45%
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ANRO vs. TOI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ANRO
ANRO Risk / Return Rank: 9999
Overall Rank
ANRO Sharpe Ratio Rank: 100100
Sharpe Ratio Rank
ANRO Sortino Ratio Rank: 9999
Sortino Ratio Rank
ANRO Omega Ratio Rank: 9898
Omega Ratio Rank
ANRO Calmar Ratio Rank: 100100
Calmar Ratio Rank
ANRO Martin Ratio Rank: 100100
Martin Ratio Rank

TOI
TOI Risk / Return Rank: 8585
Overall Rank
TOI Sharpe Ratio Rank: 8888
Sharpe Ratio Rank
TOI Sortino Ratio Rank: 8787
Sortino Ratio Rank
TOI Omega Ratio Rank: 8181
Omega Ratio Rank
TOI Calmar Ratio Rank: 8888
Calmar Ratio Rank
TOI Martin Ratio Rank: 8383
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ANRO vs. TOI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Alto Neuroscience, Inc (ANRO) and The Oncology Institute, Inc. (TOI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


ANROTOIDifference

Sharpe ratio

Return per unit of total volatility

7.25

1.74

+5.51

Sortino ratio

Return per unit of downside risk

5.65

2.59

+3.06

Omega ratio

Gain probability vs. loss probability

1.71

1.30

+0.41

Calmar ratio

Return relative to maximum drawdown

30.09

3.40

+26.69

Martin ratio

Return relative to average drawdown

72.94

6.84

+66.10

ANRO vs. TOI - Sharpe Ratio Comparison

The current ANRO Sharpe Ratio is 7.25, which is higher than the TOI Sharpe Ratio of 1.74. The chart below compares the historical Sharpe Ratios of ANRO and TOI, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


ANROTOIDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

7.25

1.74

+5.51

Sharpe Ratio (All Time)

Calculated using the full available price history

0.03

-0.20

+0.24

Correlation

The correlation between ANRO and TOI is 0.10, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

ANRO vs. TOI - Dividend Comparison

Neither ANRO nor TOI has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

ANRO vs. TOI - Drawdown Comparison

The maximum ANRO drawdown since its inception was -91.74%, smaller than the maximum TOI drawdown of -98.79%. Use the drawdown chart below to compare losses from any high point for ANRO and TOI.


Loading graphics...

Drawdown Indicators


ANROTOIDifference

Max Drawdown

Largest peak-to-trough decline

-91.74%

-98.79%

+7.05%

Max Drawdown (1Y)

Largest decline over 1 year

-29.59%

-49.79%

+20.20%

Current Drawdown

Current decline from peak

-7.45%

-71.86%

+64.41%

Average Drawdown

Average peak-to-trough decline

-56.91%

-74.57%

+17.66%

Ulcer Index

Depth and duration of drawdowns from previous peaks

12.21%

24.75%

-12.54%

Volatility

ANRO vs. TOI - Volatility Comparison

The current volatility for Alto Neuroscience, Inc (ANRO) is 24.93%, while The Oncology Institute, Inc. (TOI) has a volatility of 28.82%. This indicates that ANRO experiences smaller price fluctuations and is considered to be less risky than TOI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


ANROTOIDifference

Volatility (1M)

Calculated over the trailing 1-month period

24.93%

28.82%

-3.89%

Volatility (6M)

Calculated over the trailing 6-month period

98.02%

60.56%

+37.46%

Volatility (1Y)

Calculated over the trailing 1-year period

131.26%

97.85%

+33.41%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

118.76%

115.13%

+3.63%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

118.76%

115.13%

+3.63%

Financials

ANRO vs. TOI - Financials Comparison

This section allows you to compare key financial metrics between Alto Neuroscience, Inc and The Oncology Institute, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00MJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober0
141.96M
(ANRO) Total Revenue
(TOI) Total Revenue
Values in USD except per share items